PDCD1 and neoplasm: Mice treated with antibody therapy (anti-GITR and anti-PD-1 Abs) or peritumoral DR-BMCs showed a modest delay in tumor growth with a median survival of 31 and 33 days, respectively, compared to untreated mice (median survival – 28 days).